Aptamer Group plc Provides Revenue Guidance for the Year Ended 30 June 2022

Aptamer Group plc is a United Kingdom-based company that develops custom affinity binders through its Optimer platform to enable new approaches in therapeutics, diagnostics and research applications. The Company's Optimer platform delivers next-generation aptamer tools that are enabling researchers and developers across the spectrum of the life sciences. Its Optimer binders have been developed for a range of applications, including therapeutic inhibitors and modulators, drug delivery vehicles, protein purification and separation, biomarker screening and validation, in vitro research, quality control analysis, pharmacokinetic and drug assays, and in vitro diagnostic assays. Its Aptamer Diagnostics division uses the Company's technology to support the development of diagnostic platforms, such as proteomics, lateral flow devices, biosensors and immunoassays, such as enzyme-linked immunosorbent assay (ELISA). Its Optimer platform supports a diverse portfolio of partners and technologies.